Published: 5 September 2019
Publications
Recent approvals of medicines containing a new active ingredient
Prescriber Update 40(3): 61
September 2019
For the period 16 April 2019 to 15 July 2019.
| Trade name (Active ingredient) |
Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Jinarc (tolvaptan) | Tablet combinationa
45 mg + 15 mg 60 mg + 30 mg 90 mg + 30 mg Tablet 15 mg 30 mg |
Autosomal dominant polycystic kidney disease (ADPKD) |
| Kisqali (ribociclib) | Film coated tablet 200 mg |
Breast cancer |
| Repatha (evolocumab) | Solution for injection 140 mg pre-filled syringe 140 mg pre-filled pen |
Hypercholesterolaemia |
| Viberzi (eluxadoline) | Film coated tablet 100 mg |
Irritable bowel syndrome with diarrhoea (IBS-D) |
- This product comes in fixed-dose combinations to facilitate the split-dose regimen.
See the Medsafe website for more information about these medicines.
Data sheets of currently marketed medicines are also available.
